Glycemic optimization may reduce lipid peroxidation independent of weight and blood lipid changes in Type 2 diabetes mellitus

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 17, Issue 5, 2004, Pages 275-279

  Neyestani, Tirang R ^a   Alipour Birgani, R ^b   Siassi, F ^c   Rajayi, M ^b   Djalali, M ^c   Mohamadi, M ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Iranian Org for Sci and Technology   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Lipid peroxidation; Malondialdehyde; Oxidative stress

Indexed keywords

ANTIDIABETIC AGENT; CARBOHYDRATE; CHOLESTEROL; FAT; GLUCOSE; GUANIDINE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PROTEIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC DIET; DIET RESTRICTION; DIET THERAPY; DIETARY FIBER; FAT INTAKE; FEMALE; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IRAN; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN INTAKE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC DIET; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID PEROXIDATION; LIPIDS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 12344304555     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hayden M.R., Tyagi S.C.: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc. Diabetol. 12: 2, 2003.
2. Chaudhuri A.: Vascular reactivity in diabetes mellitus. Curr. Diab. Rep. 2: 305-310, 2002.
3. Bonnefont-Rousselot D.: Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care 5: 561-568, 2002.
4. Aronson D., Rayfield E.J.: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc. Diabetol. 1: 1, 2002.
5. Bandyopadhyay D., Chattopadhyay A., Ghosh G., Datta A.G.: Oxidative stress-induced ischemic heart disease: protection by antioxidants. Curr. Med. Chem. 11: 369-387, 2004.
6. Picard S.: Lipoprotein glyco-oxidation. Diabetes. Metab. 21: 89-94, 1995.
7. Liu S., Willet W.C.: Dietary load and atherothrombotic risk. Curr. Atheroscler. Rep. 4: 454-461, 2002.
8. Golden S.H., Folsom A.R., Coresh J., Sharrett A.R., Szklo M., Brancati F.: Risk factors groupins related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes. 51: 3069-3076, 2002.
9. Sakurai K., Sawamura T.: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J. Pharmoacol. Sci. 91: 182-186, 2003.
10. Mullarkey C.J., Edelstein D., Brownlee M.: Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochim. Bioph. Res. Com. 173: 932-939, 1990.
11. Ceriello A.: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26: 1589-1596, 2003.
12. Dunlop M.: Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney. Int. 77 (Suppl.): S3-S12, 2000.
13. Sakata N., Moh A., Takebayashi S.: Contribution of superoxide to reduced antioxidant activity of glycoxidative serum albumin. Heart Vessels 17: 22-29, 2002.
14. Kirkwood B.R.: Essentials of medical statistics. Blackwell Scientific Publications, London, 1988, p. 196.
15. Eisenbarth G.S.: Classification, diagnostic tests, and pathogenesis of type 1 diabetes mellitus. In: Becker K. (Ed.), Principles and practice of endocrinology and metabolism, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, 2001, p. 1308.
16. The American Diabetes Association: Exchange lists for meal planning. The American Dietetic Association, 1995.
17. Satoh K.: Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta. 90: 37-43, 1978.
18. Yagalla M.V., Hoerr S.L., Song W.O., Enas E.: Relationship of diet, abdominal obesity and physical activity to plasma lipoprotein levels in Asian Indian physicians residing in the United States. J. Am. Diet. Assoc. 96: 257-261, 1996.
19. Liao D., Carnethon M., Evans G.W., Cascio W.E., Heiss G.: Lower heart rate variability heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes. 51: 3524-3531, 2002.
20. Yorek M.A.: The role of oxidative stress in diabetic vascular and neural disease. Free Radic. Res. 37: 471-480, 2003.
21. Askari B., Renard C.B., Bornfeldt K.E.: Regulation of smooth muscle cell accumulation in diabetes-accelerated atherosclerosis. Histol. Histopathol. 17: 1317-1328, 2002.
22. Dimitriadis E., Griffin M., Collins P., Johnson A., Owens D., Tomkin G.H.: Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins. Diabetologia 39: 667-676, 1996.
23. Sanchez-Quesada J.L., Perez A., Caixas A., Rigla M., Payes A., Benitez S., Ordonez-Llanos J.: Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J. Clin. Endocrinol. Metab. 86: 3243-3249, 2001.
24. Kalyanaraman B.: Free radical mechanisms of oxidative modification of low-density-lipoprotein or rancidity of body. In: Ahmad S. (Ed.), Oxidative stress and antioxidant defenses in biology. Chapman & Hall, New York, 1995, pp. 96-114.
25. Witztum J.L., Steinbercher U.P., Fisher M., Kesaniemi A.: Non-enzymatic glycosylation of homologous low density lipoprotein and albumin renders them immunogenic in guinea pig. Proc. Natl. Acad. Sci. U.S.A. 80: 2747-2761, 1983.
26. Bellomo G., Maggi E., Poli M., Agosta F.G., Bollati P., Finardi G.: Autoantibodies against oxidatively modified low density lipoprotein in NIDDM. Diabetes 44: 60-66, 1995.
27. Picard S., Tallusot C., Serusdat A., Ambrosio N., Berthenzen F.: Minimally oxidized LDL as estimated by a new method increase in plasma of type 2 diabetic patients with atherosclerosis or nephropathy. Diabetes Metab. 22: 25-30, 1996.
28. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., Wong H., Peters A.L.: Glycation impairs high-density lipoprotein function. Diabetologia 43: 312-320, 2000.
29. Leinonen J.S., Rantalaiho V., Solakivi T., Koivula T., Wirta O., Pasternack A., Alho H., Lehtimaki T.: Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients. Clin. Chim. Acta. 275: 163-174, 1998.
30. Freitas J.P., Filipe P.M., Rodrigo F.G.: Lipid peroxidation in type 2 normolipidemic diabetic patients. Diabetes. Res. Clin. Pract. 3: 71-75, 1997.
31. Picard S., Parthasathy S., Fruebis J., Witztum J.L.: Aminoguanidin inhibits the oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc. Natl. Acad. Sci. U.S.A. 82: 6876-6880, 1992.
32. Bucala R.: What is the effect of hyperglycemia on atherosclerosis and can it be reversed by aminoguanidin? Diabetes Res. Clin. Pract. 30 (Suppl.): 123-130, 1996.